课题基金 / 基金详情

NATURE OF STUNNING OF THYROID TISSUE

NATURE OF STUNNING OF THYROID TISSUE
甲状腺组织致昏的性质
批准号:
7376512
负责人:
JAMES C SISSON
金额:
$0.05万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-05 至 2007-02-28

项目摘要

项目成果

JAMES C SISSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Stunning, an alteration in the kinetics of therapeutic 131-I induced by the radiation imparted from a prior diagnostic 131-I, is said to occur in residual thyroid tissues of patients with well-differentiated thyroid cancer. This research project will test the hypothesis that, in patients with thyroid cancer, the pattern of loss of 131-I from residual thyroid tissues after low amounts of 131-I (diagnostic) will differ from the pattern of loss after large amounts of 131-I (therapeutic). Ten patients who are to be treated with 131-I for their residual thyroid tissues after surgical thyroidectomies will be recruited. Serial nuclear medicine images of the tissues will be quantified to determine patterns of disappearance of diagnostic 131-I and of subsequent therapeutic 131-I, each over 7 days. An alternative protocol that was more acceptable to potential subjects was introduced: Images of the diagnostic 131-I will be obtained and quantified for only 2 days; this limited period is sufficient for comparing diagnostic and therapeutic 131-I at the time of initial uptake. The patterns should provide evidence either for stunning or, alternatively, for a radiation effect from the larger therapeutic 131-I.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RADIOIODINE TREATMENT AND GRAVES' EYE DISEASE
NATURE OF STUNNING OF THYROID TISSUE
Radioiodine Treatment and Graves' Eye Disease
IMAGING OF THYROID CANCER WITH RADIOLABELED OCTREOTIDE
海外基金